Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
about
Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insightActive surveillance for prostate cancer: current evidence and contemporary state of practiceThe quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).Coexistence of pernicious anemia and prostate cancer - 'an experiment of nature' involving vitamin B(12 )modulation of prostate cancer growth and metabolism: a case report.The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.The role of MRI in prostate cancer active surveillance.Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?Physician variation in management of low-risk prostate cancer: a population-based cohort studyWhat's a man to do? Treatment options for localized prostate cancer.Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.Our results of active surveillance for localized prostate cancer patients.Delayed versus immediate surgical intervention and prostate cancer outcomeProstate-specific antigen doubling time as a prognostic marker in prostate cancer.Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.A hospital-based study of initial observation for low-risk prostate cancer and its predictors in the United StatesActive surveillance: the Canadian experience with an "inclusive approach".Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.The Treatment of Localized Prostate Cancer in Everyday Practice in GermanyActive Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Active surveillance for prostate cancerActive surveillance or active treatment in localized prostate cancer?Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.Active surveillance for favorable-risk prostate cancer: a short review.Recent advances in magnetic resonance imaging of prostate cancer.Formalized prediction of clinically significant prostate cancer: is it possible?Early experience with active surveillance in low-risk prostate cancer treated.Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance.Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study.Early outcomes of active surveillance for localized prostate cancer.Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients.Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer.Role for (11)C-choline PET in active surveillance of prostate cancer.Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols.Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancerThe utility of provincial AS guidelines.Focal therapy for localized prostate cancer -choosing the middle ground.Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?
P2860
Q26750559-B5E1B3FC-F6E6-4EE5-90CB-7B27F5F938BCQ28066534-8964E194-D172-4C05-83D0-BB4333B9A0BDQ31083661-9CD5B634-AE72-4B8B-AD91-EFD4B6C5C4A4Q33580041-79ADCF05-7B7B-4723-BAE6-5790789ED74DQ34380870-102B48F4-DB2D-4323-80F0-A7BC94DC16C0Q34705261-907948E5-0A2B-4A10-B670-D0D5E59B5E92Q34861407-89186499-0821-4D97-9E30-99C0FF0652CBQ35213290-40DB8F4C-89C5-41F1-85C6-88E37FCE305AQ35648211-39B1AD13-6BED-465D-8AB8-039EE4733DB5Q35685712-1E60E548-640A-4313-A2AD-517C3E715FF3Q35993855-90FA521C-2DB2-463A-B9F9-F35CE105660DQ36336991-A2212ECF-81BB-493A-9DDF-EAD3C1ADAC1DQ36395092-7E691162-54DF-4D16-9838-F6157D9EBA84Q36395126-3E1AF51E-87A9-4154-B836-5AC49172E77EQ36414849-CB752C0B-FC8D-417A-A0E4-11EF8AD0578CQ36520490-A54B43AD-B2B3-46EE-AC34-2DBCBDCD81F1Q36524465-B34B349A-D5F3-4A53-A4C5-6DD58CF45968Q36833353-BA4E17D9-2B4F-4E4B-8D7A-903687EB3F6AQ36996753-145A67A6-B3F8-4770-A986-F5E4C381687EQ37029385-8481513B-A499-4422-8A07-615C32BB65CBQ37138594-CF7746B9-B3FF-4A76-81E8-3A9FAA207F8BQ37246880-A90A88E4-9834-46D9-BBAF-F26DD6EF6E8FQ37307609-24FB4CD5-04B1-4943-9DA7-43EA5EB33E9FQ37606770-D8393BED-E071-4C5B-A322-0E61C8DCA409Q37804698-B60310AA-C858-4040-8900-D7DC7AF33456Q37833928-B7B31252-5EA5-4FE4-BCF7-FEB12AAAED09Q37988363-A6531D59-B787-40EE-B6A3-423382F102BBQ38306089-13221011-E96B-4976-A2EB-9A9AA95BB67EQ38392814-D613721F-44DF-49DD-BAE9-3F7D2CE90970Q38583764-7BAA0861-753A-4893-80EE-0A8C48EE41C4Q39713992-170DDD42-A287-4618-A011-7DA0B34E24E7Q39727032-7751580B-816B-43B7-A9A2-BA5D563C09D8Q41240355-D3DF6ED4-AE7F-49E5-994B-4F1413272F29Q41816104-CC028899-06D2-4B85-B73E-C37B3D856979Q41821490-3BD44734-7825-47EC-BFA2-F93ACE560D2FQ42153467-EC8FDAAC-2F8F-413F-88BE-447B4B7268A7Q42215015-2F2E8E5C-313D-4864-9D50-C9E2F7325197Q42408017-666F0F8F-1A8B-442F-B664-6AE2607C583AQ43074409-17093A41-53B7-4165-8E1B-9BB353C42A3AQ43101073-703E808B-3C21-4350-BD39-6F89B241791A
P2860
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Feasibility study: watchful wa ...... l and/or clinical progression.
@en
Feasibility study: watchful wa ...... l and/or clinical progression.
@nl
type
label
Feasibility study: watchful wa ...... l and/or clinical progression.
@en
Feasibility study: watchful wa ...... l and/or clinical progression.
@nl
prefLabel
Feasibility study: watchful wa ...... l and/or clinical progression.
@en
Feasibility study: watchful wa ...... l and/or clinical progression.
@nl
P2093
P1476
Feasibility study: watchful wa ...... al and/or clinical progression
@en
P2093
Cyril Danjoux
Ewa Szumacher
Gerard C Morton
Gerrit DeBoer
Neil Fleshner
Peter Bunting
Richard Choo
P304
P356
10.1097/00005392-200204000-00020
P407
P577
2002-04-01T00:00:00Z